Good MorningEquity markets tried to rebound from Wednesday's unexpected selloff on Thursday but failed to regain the prior days' losses. The S&P gained 1% for the day but closed well off the highs for the week. The weekly pattern suggests a rising level of fear ahead of the PCE report, due out Friday. The PCE report is expected to confirm slowing inflation but at an insufficient pace to allow the FOMC to cut interest rates soon.
The S&P 500 price action shows resistance below the all-time high, a critical hurdle for the market. Given the proper catalyst, resistance at this level could lead to range-bound trading or a sharp correction. That catalyst could come soon, given the risk of inflation accelerating. Oil markets are already stabilizing after their correction, and ocean-going freight rates are through the roof on geopolitical concerns centered on the Red Sea. Featured: "Chilling War Games Show US Forces Crushed" – FOX NEWS (Behind the Markets) 
|
Stocks | | |
When an economic downturn arrives, many investors focus on the benefits that consumer staples can offer them. As the name suggests, consumer staples are products consumers rely on as "staples" in their daily lives. Household cleaning supplies, toiletries, and food products are all examples of cons... Read the Full Story |
|
From Our PartnersIf you’re looking for an INCREDIBLE deal on stocks with huge growth potential, now is the time to look at this list our team prepared.
(**By clicking the link you are subscribing to the Summa Money Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here)
| | | | Download The List With Details On Each Stock Here |
|
Tech | | |
Looking for new technology to invest in?
Pull up a seat and join the club.
New tech is always a popular and exciting investment idea since groundbreaking tech advancements tend to attract gobs of money. However, tech is a volatile sector, and these companies infrequently experience s... Read the Full Story |
|
Markets | | | Wall Street capped its eighth straight winning week with a quiet finish Friday, following reports showing inflation on the way down and the economy potentially on the way up.The S&P 500 rose 0.2% to sit less than 1% below its record set nearly two years ago. The Dow Jones Industrial Average sli... Read the Full Story |
|
From Our PartnersDozens of 100% - 1,000% opportunities over the last decade have led to this one under-the-radar A.I. stock... | | | | More here. |
|
Markets | | |
RV stocks have been struggling to regain traction following the social-distancing craze that drove them to record highs. The problems were rising prices and an inventory glut compounded by high interest rates.
Now, data from the RVIAA suggests that industry normalization is at hand, and gro... Read the Full Story |
|
Markets | | |
Like one of its colorful salad bowls, fast-casual restaurant chain CAVA Group Inc. (NYSE: CAVA) has been a mix of green and red since its June 2023 IPO.
The Mediterranean-themed Chipotle challenger ran nearly 60% in its first two months of trading on a healthy investor appeti... Read the Full Story |
|
From Our PartnersAI stocks have soared, and the sector's potential is just starting. By 2030, anticipate a seismic $2 trillion shift. Our special report reveals the Top 5 AI Stocks you must watch. Navigate the future of wealth. | | Stay ahead of the curve. Download your FREE report now. |
|
Markets | | | Asian shares fell Thursday after Wall Street hit the brakes on its big rally following disappointing corporate profit reports and warnings that the market had surged too far, too fast.U.S. futures rose while oil prices dipped as data showed an unexpected increase in U.S. inventories.Tokyo’s Nikkei 2... Read the Full Story |
|
Markets | | |
With just a few days left until Santa comes, shares of Micron Technology Inc (NASDAQ: MU) are set to give investors an early Christmas present. They jumped 5% in last night’s after-hours sessions off the back of the company’s fiscal Q1 earnings, which smashed analyst expectat... Read the Full Story |
|
Markets | | | The Czech Republic’s central bank cut its key interest rate Thursday hoping to give the country's struggling economy a boost.The cut by a quarter of a percentage point brought the interest rate down to 6.75%. It was the first time the bank cut the rate since June 22 last year.Last year the bank rais... Read the Full Story |
|
Markets | | | The ripple effects of the war in Gaza are likely to knock Lebanon’s fragile economy, which had begun making a tepid recovery after years of crisis, back into recession, the World Bank said in a report released Thursday.Before the outbreak of the ongoing Israel-Hamas war on Oct. 7, the World Bank had... Read the Full Story |
|
Markets | | | Turkey’s central bank hiked its key interest rate by 2.5 percentage points on Thursday as part of its efforts to combat high inflation that has left many households struggling to afford rent and essential items.The bank's Monetary Policy Committee raised its benchmark rate to 42.5%, delivering its s... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. | | View Today's Stock Pick |
|
